enGene initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado initiated coverage of enGene (ENGN) with a Buy rating and $25 price target The firm says the The non-muscle invasive bladder cancer treatment landscape is undergoing a renaissance, and enGene’s detalimogene “represents an innovative treatment option.” Detalimogene’s profile holds several competitive advantages in NMIBC, the analyst tells investors in a research note. The firm believes its expectations of efficacy for detalimogene “remain well within reach.”